[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA201690056A8 - ИСКУССТВЕННЫЕ БЕЛКИ, СВЯЗЫВАЮЩИЕ ФАКТОР Н (fHbp), И СПОСОБЫ ИХ ПРИМЕНЕНИЯ - Google Patents

ИСКУССТВЕННЫЕ БЕЛКИ, СВЯЗЫВАЮЩИЕ ФАКТОР Н (fHbp), И СПОСОБЫ ИХ ПРИМЕНЕНИЯ

Info

Publication number
EA201690056A8
EA201690056A8 EA201690056A EA201690056A EA201690056A8 EA 201690056 A8 EA201690056 A8 EA 201690056A8 EA 201690056 A EA201690056 A EA 201690056A EA 201690056 A EA201690056 A EA 201690056A EA 201690056 A8 EA201690056 A8 EA 201690056A8
Authority
EA
Eurasian Patent Office
Prior art keywords
fhbp
factor
artificial
methods
variant
Prior art date
Application number
EA201690056A
Other languages
English (en)
Other versions
EA201690056A1 (ru
Inventor
Питер Т. Бирнинк
Original Assignee
Чилдренс Хоспитл Энд Рисерч Сентер Эт Окленд
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Чилдренс Хоспитл Энд Рисерч Сентер Эт Окленд filed Critical Чилдренс Хоспитл Энд Рисерч Сентер Эт Окленд
Publication of EA201690056A1 publication Critical patent/EA201690056A1/ru
Publication of EA201690056A8 publication Critical patent/EA201690056A8/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Biotechnology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)

Abstract

Предложен искусственный белок, связывающий фактор Н, полученный из fHbp-вариант 3, который может индуцировать антитела, обладающие бактерицидными свойствами в отношении по меньшей мере одного штамма N. meningitidis, и способы применения таких белков. В некоторых вариантах осуществления изобретения раскрыт искусственный белок, связывающий фактор Н (fHbp), полученный из природного fHbp-вариант 3. Искусственный fHbp может содержать замену гистидина в положении 223 природного fHbp-вариант 3 аминокислотой, выбранной из группы, состоящей из аргинина, лизина, фенилаланина, тирозина или триптофана, и нумерация позиции 223 основана на нумерации зрелого fHbp ID 1. Искусственный fHbp может обладать более низким сродством к человеческому фактору Н (fH), чем fHbp ID 79.
EA201690056A 2013-08-02 2014-08-01 ИСКУССТВЕННЫЕ БЕЛКИ, СВЯЗЫВАЮЩИЕ ФАКТОР Н (fHbp), И СПОСОБЫ ИХ ПРИМЕНЕНИЯ EA201690056A8 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361861662P 2013-08-02 2013-08-02
PCT/US2014/049465 WO2015017817A1 (en) 2013-08-02 2014-08-01 Non-naturally occurring factor h binding proteins (fhbp) and methods of use thereof

Publications (2)

Publication Number Publication Date
EA201690056A1 EA201690056A1 (ru) 2016-07-29
EA201690056A8 true EA201690056A8 (ru) 2017-07-31

Family

ID=52432473

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201690056A EA201690056A8 (ru) 2013-08-02 2014-08-01 ИСКУССТВЕННЫЕ БЕЛКИ, СВЯЗЫВАЮЩИЕ ФАКТОР Н (fHbp), И СПОСОБЫ ИХ ПРИМЕНЕНИЯ

Country Status (13)

Country Link
US (1) US9914756B2 (ru)
EP (1) EP3027206A4 (ru)
JP (1) JP2016527278A (ru)
KR (1) KR20160034401A (ru)
CN (1) CN105431167A (ru)
AU (1) AU2014296027A1 (ru)
BR (1) BR112016002150A2 (ru)
CA (1) CA2918547A1 (ru)
EA (1) EA201690056A8 (ru)
IL (1) IL243535A0 (ru)
MX (1) MX2016001412A (ru)
SG (1) SG11201600334SA (ru)
WO (1) WO2015017817A1 (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2922554T3 (es) 2014-07-23 2022-09-16 Childrens Hospital & Res Center At Oakland Variantes de proteínas de unión al factor H y métodos de uso de las mismas
EP3298031B1 (en) * 2015-05-18 2020-10-21 BiOMVis Srl Immunogenic compositions containing bacterial outer membrane vesicles and therapeutic uses thereof
KR101865757B1 (ko) 2017-12-06 2018-06-08 김기성 저영향개발형 수처리장치
EP4294432A1 (en) 2021-02-19 2023-12-27 Sanofi Pasteur, Inc. Meningococcal b recombinant vaccine
TW202423477A (zh) 2022-08-03 2024-06-16 美商賽諾菲巴斯德公司 針對腦膜炎奈瑟氏菌b的含佐劑免疫原性組成物
WO2024095289A1 (en) * 2022-11-04 2024-05-10 Techinvention Lifecare Private Limited Mutated factor H binding proteins (fHbp) of Neisseria meningitidis, their compositions and use thereof.

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070026021A1 (en) 1998-05-01 2007-02-01 Chiron S.R.I. Neisseria meningitidis antigens and compositions
PT1944371E (pt) 1998-05-01 2015-07-13 Novartis Ag Antigénios e composições da neisseria meningitidis
AU2013206190A1 (en) * 1999-11-29 2013-06-27 Novartis Vaccines And Diagnostics S.R.L. Compositions comprising Neisseria meningitidis antigens from serogroups B and C as well as a further antigen
PT1248647E (pt) 2000-01-17 2010-11-18 Novartis Vaccines & Diagnostics Srl Vacina de vesícula da membrana externa (omv) compreendendo proteínas de membrana externa de n. meningitidis do serogrupo b
GB0121591D0 (en) * 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
US7785608B2 (en) 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
DE60335477D1 (de) 2002-10-11 2011-02-03 Novartis Vaccines & Diagnostic Polypeptidimpstoffe zum breiten schutz gegen hypervirulente meningokokken-linien
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
WO2005064021A2 (en) 2003-12-23 2005-07-14 Glaxosmithkline Biologicals S.A. Vaccine
GB0419408D0 (en) 2004-09-01 2004-10-06 Chiron Srl 741 chimeric polypeptides
PT2682126T (pt) 2005-01-27 2017-02-28 Children`S Hospital & Res Center At Oakland Vacinas de vesícula com base em agn1870 para proteção de amplo espetro contra doenças causadas por neisseria meningitidis
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
WO2009038889A1 (en) 2007-08-02 2009-03-26 Children's Hospital And Research Center At Oakland Fhbp- and lpxl1-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
WO2009104097A2 (en) 2008-02-21 2009-08-27 Novartis Ag Meningococcal fhbp polypeptides
CA2717870A1 (en) 2008-03-10 2009-09-17 Children's Hospital & Research Center At Oakland Chimeric factor h binding proteins (fhbp) containing a heterologous b domain and methods of use
AU2009288242A1 (en) 2008-08-27 2010-03-11 Children's Hospital & Research Center At Oakland Complement factor H-based assays for serum bactericidal activity against Neisseria meningitidis
EP2331562A4 (en) * 2008-09-03 2012-07-04 Childrens Hosp & Res Ct Oak PEPTIDES WITH AN EPITOPE OF A DOMAIN OF THE FACTOR H-BINDING PROTEIN AND METHOD OF USE
IT1394288B1 (it) 2008-09-12 2012-06-06 Novartis Vaccines & Diagnostic Immunogeni di proteine che legano il fattore h.
GB0819633D0 (en) 2008-10-25 2008-12-03 Isis Innovation Composition
SI2411048T1 (sl) 2009-03-24 2020-08-31 Glaxosmithkline Biologicals Sa Meningokokni faktor H vezavni protein uporabljen kot adjuvans
MX2011011512A (es) 2009-04-30 2012-02-13 Novartis Vaccines & Diagnostic Proteinas de union de factor h quimericas (fhbp) y metodos de uso.
BR112012010531A2 (pt) * 2009-10-27 2019-09-24 Novartis Ag "polipeptídeos de modificação meningocócica fhbp"
WO2011126863A1 (en) 2010-03-30 2011-10-13 Children's Hospital & Research Center Oakland Factor h binding proteins (fhbp) with altered properties and methods of use thereof
ES2670669T3 (es) 2011-07-07 2018-05-31 De Staat Der Nederlanden, Vert. Door De Minister Van Vws Proceso para la producción sin detergente de vesículas de membrana externa de una bacteria gram-negativa
WO2013078223A1 (en) 2011-11-23 2013-05-30 Children's Hospital & Research Center Oakland Anti-factor h binding protein antibodies and methods of use thereof

Also Published As

Publication number Publication date
SG11201600334SA (en) 2016-02-26
MX2016001412A (es) 2016-10-28
AU2014296027A1 (en) 2016-02-04
US20160159865A1 (en) 2016-06-09
BR112016002150A2 (pt) 2017-09-12
CN105431167A (zh) 2016-03-23
WO2015017817A1 (en) 2015-02-05
EP3027206A4 (en) 2017-03-08
JP2016527278A (ja) 2016-09-08
KR20160034401A (ko) 2016-03-29
EA201690056A1 (ru) 2016-07-29
IL243535A0 (en) 2016-03-31
US9914756B2 (en) 2018-03-13
EP3027206A1 (en) 2016-06-08
CA2918547A1 (en) 2015-02-05

Similar Documents

Publication Publication Date Title
EA201690056A1 (ru) ИСКУССТВЕННЫЕ БЕЛКИ, СВЯЗЫВАЮЩИЕ ФАКТОР Н (fHbp), И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
PH12018501882A1 (en) Binding proteins and methods of use thereof
EA201100546A1 (ru) Полипептиды, вариабельные домены антител и антагонисты
EA201100070A1 (ru) Туберкулезный белок rv2386c, композиции и их применения
EA201892548A1 (ru) Антитела к альфа-синуклеину и их применение
EA201590627A1 (ru) Антитела, распознающие альфа-синуклеин
UA107330C2 (ru) Туберкулезный белок rv3616c и его применение
EA201291180A1 (ru) Композиции и способы применения терапевтических антител против белка, родственного рецептору липопротеинов низкой плотности 6 (lrp6)
EA201491049A1 (ru) Противораковый слитый белок
BR112016011025A2 (pt) polipeptídeos anticorpo e seus usos
NZ766005A (en) Factor h binding protein variants and methods of use thereof
CY1123997T1 (el) Νεα μεταλλακτικη παραλλαγη αλβουμινης ανθρωπινου ορου
WO2008124646A3 (en) Use of amyloid proteins as vaccine scaffolds
EA201390820A1 (ru) Слитый белок против рака
EA201100071A1 (ru) Новые композиции и способы
CO6400235A2 (es) Tensiactivos reconstituidos que tienen propiedades mejoradas
PL415888A1 (pl) Sposób wytwarzania insuliny i jej pochodnych oraz peptyd hybrydowy stosowany w tym sposobie
EA201790341A1 (ru) Анти-ск8 антитела для применения в лечении рака
EA202192925A1 (ru) Твердые формы ингибитора glyt1
MX2014004132A (es) Señuelos humanos notch1.
BR112014028130A2 (pt) Sal de cloridrato de um peptídeo, composição farmacêutica, uso de um sal de cloridrato, uso de uma composição farmacêutica, e, método para evitar ou tratar alergia a gatos
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
NZ762312A (en) Anti-pacap antibody
IN2015DN03883A (ru)
PH12019502449A1 (en) Anti-jagged1 antigen binding proteins